Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030
So you're thinking of investing in Eli Lilly(NYSE: LLY) stock and you're wondering how it will perform by 2030 -- about four years from now. No one can know exactly how any stock will perform over a certain period. Still, we can certainly make an educated guess.
We might start by looking at how the stock has performed in the past:
Missed AI's "Act 1"? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
| Period |
Average Annual Gain |
|---|---|
| Past 3 years |
32.37% |
| Past 5 years |
39.20% |
| Past 10 years |
33.02% |
| Past 15 years |
26.78% |
Source: Morningstar.com, as of Oct. 27, 2026.
It's worth keeping in mind that these growth rates are far above the long-term average annual gains for the overall stock market , which have been closer to 10%.
They're steep in large part because Lilly's home to some blockbuster GLP-1 weight-loss drugs such as Mounjaro and Zepbound. Those robust sales may continue for the foreseeable future, with Morgan Stanleyforecasting that the global market for GLP-1 drugs could more than double between 2025 and 2035, to $190 billion. There's competition, though, such as from Novo Nordisk's(NYSE: NVO) Ozempic and Wegovy.
To be somewhat conservative, let's not assume annual growth topping 30%. Let's go with, say, 25% instead. Let's also assume you invest $100 per month (that's $1,200 annually) in Eli Lilly stock for four years. Come late 2030, what will your stake be worth? The answer is... close to $8,000. You would have invested $4,800 and the rest would be your gain -- some 67% over four years.
Here's another consideration: At recent levels, Eli Lilly stock may be overvalued. Its price-to-sales ratio, for example, is 14.4, above its five-year average of 13.3. Its price-to-earnings (P/E) ratio of 43 is below its five-year average of 58, but all of these numbers are on the steep side. The current valuation may actually be reasonable -- assuming all goes well for the company. But a pullback is certainly possible, and that would affect our growth projection.
Eli Lilly is well worth considering for your portfolio, but learn more about it first.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $334,793!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,257,420!*
Now, it's worth noting Stock Advisor's total average return is 874% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor , and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of October 31, 2026.
Selena Maranjian has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy .
Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030 was originally published by The Motley Fool
